Atlas Trials

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Clinical trial NCT03201250 · TERMINATED

Trial details

NCT number
NCT03201250
Sponsor
University of Nebraska
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple MyelomaRefractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma
Start date
2018-02-21
Primary completion
2021-04-12
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.